Results 121 to 130 of about 1,464,526 (284)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Correction: Mechanisms that Trigger a Good Health-Care Response to Intimate Partner Violence in Spain. Combining Realist Evaluation and Qualitative Comparative Analysis Approaches

PLOS ONE, 2015
Isabel Goicolea, Carmen Vives-Cases, Anna-Karin Hurtig, Bruno Marchal, Erica Briones-Vozmediano, Laura Otero-García, Marta García-Quinto, Miguel San Sebastian   +7 more
openaire   +4 more sources

Comparison of patient evaluations of health care quality in relation to WHO measures of achievement in 12 European countries

Bulletin of the World Health Organization, 2004
OBJECTIVES: To gain insight into similarities and differences in patient evaluations of quality of primary care across 12 European countries and to correlate patient evaluations with WHO health system performance measures (for example, responsiveness) of
Kerssens Jan J., Groenewegen Peter P., Sixma Herman J., Boerma Wienke G.W., Eijk Ingrid van der   +4 more
doaj  

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

PCN37 IMPACT OF HEALTH CARE REFORMSAND CHANGING PAYMENT MECHANISMS ON HEALTH ECONOMIC EVALUATIONS IN GERMANY

Value in Health, 2005
Hieke, K, Grothey, A
openaire   +1 more source

Namibia research situation analysis on orphans and other vulnerable children [PDF]

, 2009
This item is archived in the repository for materials published for the USAID supported Orphans and Vulnerable Children Comprehensive Action Research Project (OVC-CARE) at the Boston University Center for Global Health and Development.Addressing the ...
Beard, Jennifer, Beukes, Crystal, Biemba, Godfrey, Brooks, Bram, Costello, Jill, De Beer, Ingrid, Lokhorst, Bertine, Mollers, Madelief, Simon, Jonathon   +8 more
core  

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Experiences of group antenatal care in the context of the NHS in England: what are the mechanisms by which it functions in this context?

Frontiers in Global Women's Health
IntroductionGroup antenatal care is a model where care is provided in groups of around 6–12 women/birthing people, integrating healthcare with information and learning in a participatory approach.
Christine McCourt, Christine McCourt, Anita Mehay, Octavia Wiseman, Jalana Lazar, Ruth Ajayi, Thomas Hamborg, Vivian Holmes, Rachael Maree Hunter, Ekaterina Mishareva, Pearl Safo Sobre, Meg Wiggins, Angela Harden, Cathy Salisbury, Bethan Hatherall   +14 more
doaj   +1 more source